21181 ⎘
Medicinal preparations containing antigens or antibodies characterised by the route of administration; Mucosal route intranasal
Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
#302Recombinant respiratory syncytial virus stains with mutations in the M2-2 ORF providing a range of attenuation phenotypes
#303Functional influenza virus-like particles (VLPS)
#304Attenuated infectious bronchitis virus
#305Cancer vaccine compositions and methods of using the same
#306Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
#307ATTENUATED MANNHEIMIA HAEMOLYTICA STRAINS
#308PRRSV SX-105 strain and use thereof
#309Compositions and methods of treating sarcoma lung metastasis
#310Anti-infection and anti-tumor mucosal immune preparation
#311Bovine herpesvirus type 1 (BoHV-1) vector against bovine respiratory disease complex
#312CHIKV RNA vaccines
#313INFLUENZA VIRUS VACCINES AND USES THEREOF
#314Vaccine compositions
#315Immunogenic compositions and uses thereof
#316Prefusion RSV F proteins and their use
#317Method of vaccination with an attenuated RSV vaccine formulation
#318H3 influenza A virus
#319Bivalent swine influenza virus vaccine
#320Zika RNA vaccines
#321Live attenuated oral vaccine against shigellosis and typhoid fever
#322Methods of treating and preventing influenza infections
#323Viral vaccines and methods of forming the same
#324Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
#325Nanoparticle based vaccine strategy against swine influenza virus
#326POLYNUCLEOTIDES FOR TREATING ONCOGENIC VIRAL POLYPEPTIDE POSITIVE TUMORS
#327Influenza vaccines
#328Fusion proteins and combination vaccines comprising haemophilus influenzae Protein E and Pilin A
#329Treatment of mammalian physiological reaction of IgE antibodies present in said mammal upon contact with the corresponding antigen
#330Live attenuated Arkansas serotype infectious bronchitis virus vaccine
#331Respiratory syncytial virus with a genomic deficiency complemented in trans
#332Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
#333Peptides derived from acinetobacter baumannii and their use in vaccination
#334Methods and products for treating and/or delaying onset of dysplastic lesions
#335Sprayer technology
#336Non-gelatin vaccine protectant composition and live attenuated influenza vaccine
#337Vaccine composition for treating or preventing shigellosis
#338Streptococcal vaccine
#339Fungal immunogens and related materials and methods
#340Functional influenza virus like particles (VLPs)
#341Methods to improve induction of IgA antibodies by vaccines
#342Chimeric peptides against HTLV-1
#343CHLAMYDIA ANTIGENS
#344Mutated
#345Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
#346Anti-vaccine using sendai virus as vector
#347Promoters
#348Methods and compositions employing immunogenic fusion proteins
#349Display platform from bacterial spore coat proteins
#350DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS
#351Influenza virus vectors and uses therefor
#352H3 influenza A virus
#353NOVEL INFLUENZA VIRUS
#354Binding molecules directed against influenza hemagglutinin and uses thereof
#355Influenza virus vaccination regimens
#356THERAPEUTIC VACCINES FOR TREATING HERPES SIMPLEX VIRUS TYPE-2 INFECTIONS
#357Human ebola virus species and compositions and methods thereof
#358Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine
#359Compositions comprising an anti-C5 antibody
#360DISRUPTION OF THE INTERACTION BETWEEN AMYLOID BETA PEPTIDE AND DIETARY LIPIDS
#361COMPOSITION COMPRISING PEDV ANTIGENS AND METHODS FOR MAKING AND USING THE COMPOSITION
#362COMPOSITION AND METHODS BASED ON NEUTRALIZING ANTIBODIES DELIVERED INTRANASALLY FOR ENHANCED THERAPEUTIC EFFICACY
#363Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine
#364Composition comprising antigens and a mucosal adjuvant and a method for using
#365AGENT FOR CONTROLLING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME
#366Attenuated strains
#367Methods for treating plague
#368Attenuated Bordetella strains
#369Compositions and methods for enhanced innate immunity
#370Attenuated bovine coronavirus and related vaccines
#371Transgenic Vero-CD4/CCR5 cell line
#372Optimized HIV envelope gene and expression thereof
#373FUSION PROTEIN COMPRISING STREPTOCOCCAL ANTIGEN
#374Dual purpose universal influenza vaccine confers protective immunity against anthrax
#375Functional influenza virus-like particles (VLPS)
#376Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
#377Method of quickly producing antibodies against avian influenza and maintain antibody titer of duck
#378Attenuated vaccines and methods of making and use
#379METHODS AND COMPOSITIONS TO PRODUCE VACCINES AGAINST SMALLPOX IN PLANTS
#380Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that include thrombosis treatment drug
#381Newcastle disease virus vectored avian vaccines
#382Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
#383Vaccine for PCV2 and mycoplasma
#384Adjuvant for mucosal vaccine
#385Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
#386Compositions and methods for enterohemorrhagic (EHEC) vaccination
#387Composite antigenic sequences and vaccines
#388Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
#389Influenza virus hemagglutinin protein as a vaccine antigen
#390Immunological compositions containing attenuated
#391Immunity inducer
#392Attenuated African swine fever virus vaccine
#393Compositions and methods for treatment of microbial infections
#394Nasal delivery device
#395Polyvalent influenza virus-like particles (VLPS) and use as vaccines
#396Attenuated Mannheimia haemolytica Vaccines and Methods of Making and Use
#397Rhinal spray nozzle used for medical syringe
#398Rhinovaccination system of influenza vaccine
#399H3 influenza A virus
#400Influenza virus vectors and uses therefor
#401Induction of mucosal tolerance to antigens
#402Replication-competent VSV-HIV Env vaccines
#403Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
#404Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#405Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
#406Method of treating protozoal gastrointestinal disorders in immunocompromised patients
#407West Nile Virus vaccine
#408Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
#409Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#410Multi-functional mucosal vaccine platform
#411Fusion proteins and combination vaccines comprising protein E and pilin A
#412Nasal vaccine for
#413Mutated
#414Immunomodulatory compounds
#415Methods and compositions for nanoemulsion vaccine formulations
#416Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
#417Polynucleotides for treating oncogenic viral polypeptide positive tumors
#418Immunogenic compositions and methods
#419Cedar virus and methods of use
#420Influenza virus vaccines and uses thereof
#421Respiratory syncytial virus vaccine
#422Recombinant low virulence bovine herpesvirus-1 (BoHV-1) vaccine vectors
#423Adjuvant for mucosal vaccine
#424Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
#425Gene-deleted variant strain of porcine pseudorabies virus, vaccine composition, method of making the same and use thereof
#426Immunogenic compositions and uses thereof
#427Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
#428Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica
#429Gene-deleted variant strain of porcine pseudorabies virus, vaccine composition, method of making the same and use thereof
#430Albumin variants and uses thereof
#431ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS
#432Use of Acid Stable Proteases in Animal Feed, Preferably to Increase Performance of COCC-Vaccinated Broiler Chickens
#433Bivalent swine influenza virus vaccine
#434Fusion proteins and combination vaccines comprising Protein E and Pilin A
#435Attenuated strains
#436Nasal mucosal vaccine composition
#437Influenza virus mutants and uses therefor
#438Influenza virus mutants and uses therefor
#439Mucosal vaccine composition
#440Treatment of mammalian physiological reaction of IgE antibodies present in said mammal upon contact with the corresponding antigen
#441Attenuated mannheimia haemolytica vaccines and methods of making and use
#442Designed peptides for tight junction barrier modulation
#443Recombinant polypeptide construct comprising multiple enterotoxigenic fimbrial subunits
#444Efficient mucosal vaccination mediated by the neonatal Fc receptor
#445Intranasal vaccination dosage regimen
#446Adjuvant compositions and methods of use
#447Chlamydia antigens
#448Universal influenza vaccine
#449Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
#450Neutralizing molecules to influenza viruses
#451Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
#452Vaccine against streptococcal infections based on recombinant proteins
#453Korean-type porcine reproductive and respiratory syndrome (PRRS) virus
#454Nanoemulsion influenza vaccine
#455Fungal immunogens and related materials and methods
#456Prefusion RSV F proteins and their use
#457Attenuated strains
#458immunogens and related materials and methods
#459Methods and compositions employing immunogenic fusion proteins
#460Rapid and prolonged immunologic-therapeutic
#461NASAL INFLUENZA VACCINE COMPOSITION
#462Functional influenza virus-like particles (VLPS)
#463Norovirus vaccine formulations
#464Vault compositions for immunization
#465Nanoparticle-based compositions
#466Functional influenza virus like particles (VLPs)
#467Influenza virus vaccines and uses thereof
#468Respiratory syncytial virus with a genomic deficiency complemented in trans
#469Dose selection of adjuvanted synthetic nanocarriers
#470Nasal vaccine against the development of atherosclerosis disease and fatty liver
#471Vaccination against
#472Influenza viruses with mutant PB2 segment as live attenuated vaccines
#473Vaccine composition for naive subjects
#474POLYVALENT INFLUENZA VIRUS-LIKE PARTICLE (VLP) COMPOSITIONS
#475RSV mucosal vaccine
#476Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
#477Gonorrheal MtrE peptides and vaccines
#478Influenza vaccines
#479Universal influenza vaccine based on heterologous multiple M2E proteins
#480Compositions and methods for vaccination
#481Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
#482Pharmaceutical composition comprising a solid nanoparticle and at least an antigen for the treatment against an intracellular pathogenic agent
#483Anti-HER2 vaccine based upon AAV derived multimeric structures
#484Human Ebola virus species and compositions and methods thereof
#485Recombinant strains
#486Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#487NOVEL PRIME-BOOSTING REGIMENS INVOLVING IMMUNOGENIC POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES
#488Method of using attenuated bordetella strains
#489Vaccine vectors and methods of enhancing immune responses
#490Immunogenic compositions and methods of use thereof
#491Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
#492Fusion proteins and combination vaccines comprising Protein E and Pilin A
#493Fusion proteins and combination vaccines comprising Protein E and Pilin A
#494Composition comprising a colloidal synthetic bioresorbable vector and a viral vector
#495vaccine combination
#496Antigen delivery vectors and constructs
#497Recombinant polypeptide construct comprising multiple enterotoxigenic fimbrial subunits
#498Paramyxovirus immunogens and related materials and methods
#499MULTIVALENT NANOEMULSION VACCINES
#500Immunogenic compositions and methods
#501Alphavirus vectors for respiratory pathogen vaccines
#502Polynucleotides for treating oncogenic viral polypeptide positive tumors
#503Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
#504Timothy grass allergens and methods and uses for immune response modulation
#505Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#506Influenza virus vaccines and uses thereof
#507Norovirus immunogens and related materials and methods
#508Induction of mucosal tolerance to antigens
#509Induction of mucosal tolerance to antigens
#510Live, attenuated strain and vaccine for protection against pneumococcal disease
#511Use of GK-1 peptide expressed on M13 filamentous phage as pharmaceutical ingredient to enhance the efficiency of the immune response induced by vaccine or pathogen antigens
#512Norovirus vaccine formulations
#513Influenza virus-like particle (VLP) compositions
#514Treatment of mammalian physiological reaction of IgE antibodies present in said mammal upon contact with the corresponding antigen
#515Compositions and methods for treating clostridium difficile-associated diseases
#516Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
#517Newcastle disease virus vectored avian vaccines
#518Multivalent vaccines for rabies virus and filoviruses
#519Therapeutic vaccines for treating herpes simplex virus type-2 infections
#520Functional influenza virus-like particles (VLPs)
#521Attenuated mannheimia haemolytica vaccines and methods of making and use
#522Carious tooth vaccine and preparation method
#523Recombinant influenza viruses and constructs and uses thereof
#524Recombinant low virulence bovine herpesvirus-1 (BoHV-1) vaccine vectors
#525Rapid and prolonged immunologic-therapeutic
#526Influenza virus mutants and uses therefor
#527Vaccine and drug delivery by intranasal application of vector and vector extracts
#528Immunogenic compositions in particulate form and methods for producing the same
#529Chlamydia antigens
#530Mucosal immunization
#531Fusion proteins and combination vaccines comprising Protein E and Pilin A
#532High concentration antibody formulations
#533Methods and compositions employing immunogenic fusion proteins
#534Protein complex system for increased immunogenicity and functionality, and methods making and use
#535Recombinant mumps virus vaccine
#536Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
#537Respiratory syncytial virus vaccine
#538Mucosal adjuvant composition
#539Norovirus vaccine formulations
#540Method of conferring a protective immune response to Norovirus
#541Methods and compositions for intranasal delivery
#542Norovirus vaccine formulations
#543Antigen-Norovirus P-domain monomers and dimers, antigen Norovirus P-particle molecules, and methods for their making and use
#544Methods and compositions to produce vaccines against smallpox in plants
#545Vaccine against streptococcal infections based on recombinant proteins
#546Immunogenic composition
#547Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration
#548Adjuvant compositions and methods of use
#549Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant
#550Interferon-inducing porcine reproductive and respiratory syndrome virus isolate
#551Chimeric adenoviral vectors
#552Method of preventing or treating influenza A viral infection using cloned DI influenza A viral particles
#553Cholera toxin chimera and its use as a staph vaccine
#554Broadly protective vaccine based on type III secretion apparatus proteins
#555Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
#556Humanized antibodies to iNKT
#557Methods and compositions for intranasal delivery
#558V. Cholera hypereexpressing recombinant cholera toxin B subunit showing dual immunogenicity
#559Stabilized virus like particles having enhanced mucosal immunogenicity
#560YEAST-BASED VACCINES AS IMMUNOTHERAPY
#561Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine
#562METHODS OF TREATING ALLERGIES WITH SUBSTANTIALLY PHENOL-FREE CARRIERS
#563Mucosal vaccines
#564ADJUVANT CONTAINING beta-HEMATIN
#565Recombinant baculovirus vaccine
#566Human respiratory syncytial virus vaccine
#567METHODS FOR PREVENTING AND TREATING STAPHYLOCOCCUS AUREUS COLONIZATION, INFECTION, AND DISEASE
#568Antigen delivery vectors and constructs
#569FORMULATION OF HEPATITIS B VIRUS ANTIGENS FOR CELLULAR STIMULATION FOLLOWED BY THERAPEUTIC IMMUNIZATION
#570METHOD OF MAKING AND USING A COMPOSITION FOR DELIVERING VIRAL IMMUNOGEN IMMUNOGLOBULIN INHIBITOR TO THE NASAL PHARYNGEAL MEMBRANE
#571Vaccine and health-related applications for ruminant breath monitoring system
#572FUNCTIONAL MUTATION IN RESPIRATORY SYNCYTIAL VIRUS
#573Vaccine vectors and methods of enhancing immune responses
#574USE OF NEWCASTLE DISEASE VIRUS-BASED VECTOR FOR INDUCING AN IMMUNE RESPONSE IN MAMMALS
#575Rapid and prolonged immunologic-therapeutic
#576ATTENUATED INFLUENZA VIRUSES AND VACCINES
#577Topical Methods Of Treating RSV Infections And Related Conditions
#578IMMUNOGENIC COMPOSITIONS COMPRISING NANOEMULSION AND HEPATITIS B VIRUS IMMUNOGEN AND METHODS OF USING THE SAME
#579Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#580Selectively disrupted whole-cell vaccine
#581Compositions and methods for preventing or treating infection
#582Human Ebola Virus Species and Compositions and Methods Thereof
#583IMMUNIZATION STRATEGY TO PREVENT H1N1 INFECTION
#584IMMUNOGENIC COMPOSITION AND METHODS
#585Bacterial spore having therapeutic agent adsorbed on its surface
#586High concentration formulations of anti-C5 antibodies
#587Adjuvanted vaccine formulations
#588INTRANASAL SPRAY-TYPE TUBERCULOSIS VACCINE USING PARAMYXOVIRUS VECTOR
#589Efficient mucosal vaccination mediated by the neonatal Fc receptor
#590Functional influenza virus-like particles (VLPs)
#591Peptide, adjuvants, vaccines, and methods of use
#592Multi plasmids system for the production of influenza virus
#593Microbial vaccine and vaccine vector
#594Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
#595Uses of Yerba Santa
#596IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES
#597Method of preparing live viral vaccines by genetic engineering of viral genome
#598Influenza virus
#599Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles
#600Norovirus vaccine formulations